American Health Packaging (United States) has no DMF, CEP or site registration linked in our records. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “American Health Packaging: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/american-health-packaging

Overview

American Health Packaging is a pharmaceutical company headquartered in Columbus, United States.

FDA compliance signals

50 FDA enforcement records linked to this company.

  • recall — Class II2026-10-21

    Presence of Foreign Tablets/Capsules

  • recall — Class III2026-09-09

    Labeling: Label Mix-up

  • recall — Class III2022-05-25

    Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to dissolution failure at 0-time of the repackaged lot. Drug release results were above specification at 0-time.

  • recall — Class III2022-05-04

    Subpotent Drug: Out of specification for assay.

  • recall — Class II2022-03-16

    Impurity failure at 0-time of the repackaged lot.

  • recall — Class II2022-02-02

    Failed Dissolution Specifications

  • recall — Class II2021-10-27

    Failed Dissolution Specifications: results were above specification.

  • recall — Class II2021-10-06

    CGMP Deviations: Potential concern with products manufactured using liquid sugar batches contaminated with microbial organisms.

  • recall — Class III2021-09-29

    Failed Impurities/Degradation Specifications

  • recall — Class II2021-01-27

    Failed Dissolution Specifications

  • recall — Class III2020-07-01

    Labeling Not Elsewhere Classified: The statement Pharmacist: Dispense with the accompanying Medication Guide was not included on the carton label.

  • recall — Class II2020-06-17

    Failed dissolution specification - dissolution results of 59% (spec. NLT 85%) at the 24 month time point (end of shelf life).

  • recall — Class II2020-03-18

    CGMP Deviations: Potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

  • recall — Class II2020-02-26

    GMP Deviations: Product bottle may be absent of desiccant.

  • recall — Class II2020-02-26

    GMP Deviations: Product bottle may be absent of desiccant.

  • recall — Class II2020-02-19

    Failed Dissolution Specifications: Low out of specification results obtained during stability testing.

  • recall — Class II2020-01-08

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class III2019-09-18

    Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the insert that incorrectly lists the tablet description coding for the tablets.

  • recall — Class II2019-08-21

    Failed Dissolution Specifications

  • recall — Class II2019-08-21

    Failed Impurities/Degradation Specifications; out of specification result for an unknown impurity in stability samples.

  • recall — Class III2019-08-14

    CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results.

  • recall — Class II2019-08-07

    Failed Dissolution Specifications: Out of specification result for the dissolution test.

  • recall — Class II2019-07-17

    GMP Deviations: Potential cross contamination due to cleaning procedure failure.

  • recall — Class II2019-07-03

    GMP Deviations; possible cross contamination of product due to cleaning procedure failure.

  • recall — Class II2019-07-03

    GMP Deviations; possible cross contamination of product due to cleaning procedure failure.

  • recall — Class II2019-07-03

    GMP Deviations; possible cross contamination of product due to cleaning procedure failure.

  • recall — Class II2019-07-03

    GMP Deviations; possible cross contamination of product due to cleaning procedure failure.

  • recall — Class II2019-06-26

    GMP Deviations: Potential cross contamination due to cleaning procedure failure.

  • recall — Class II2019-05-08

    Failed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.

  • recall — Class II2019-03-27

    CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.

  • recall — Class III2018-11-28

    Cross contamination with other products: This sub-recall is being initiated in support of the recall by the manufacturer (Sandoz) dated 11/1/18, which included lots that were repackaged by American Health Packaging. Sandoz stated that "These lots are being recalled due to the potential presence of unrelated ingredients (i.e. traces of active ingredients of Benazepril, Haloperidol and Perphenazine), which were identified through a manufacturing investigation."

  • recall — Class III2018-07-18

    Failed Impurities/Degradation Specification; out-of-specification results for the Enalapril DKT degradant

  • recall — Class II2018-02-21

    CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.

  • 4832017-06-15

    SOPs not followed / documented

  • 4832017-06-15

    Procedures not in writing, fully followed

  • 4832017-06-15

    Procedures to be written and followed

  • recall — Class III2015-07-22

    Tablets/Capsules Imprinted with Wrong ID: Some tablets incorrectly imprinted with an X on one side.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

  • recall — Class II2015-07-15

    CGMP Deviations: Firm did not adequately investigate customer complaints.

For suppliers

Is this American Health Packaging?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.